Pui Ching-Hon, Jeha Sima
Department of Oncology, St Jude Children's Research Hospital, 332 North Lauderdale Street, Memphis, Tennessee 38105, USA.
Nat Rev Drug Discov. 2007 Feb;6(2):149-65. doi: 10.1038/nrd2240.
Although contemporary treatments cure more than 80% of children with acute lymphoblastic leukaemia (ALL), some patients require intensive treatment and many patients still develop serious acute and late complications owing to the side effects of the treatments. Furthermore, the survival rate for adults with ALL remains below 40%. Therefore, new treatment strategies are needed to improve not only the cure rate but also the quality of life of these patients. Here, we discuss emerging new treatments that might improve the clinical outcome of patients with ALL. These include new formulations of existing chemotherapeutic agents, new antimetabolites and nucleoside analogues, monoclonal antibodies against leukaemia-associated antigens, and molecular therapies that target genetic abnormalities of the leukaemic cells and their affected signalling pathways.
尽管当代治疗方法能治愈超过80%的急性淋巴细胞白血病（ALL）患儿，但一些患者仍需要强化治疗，而且由于治疗的副作用，许多患者仍会出现严重的急性和晚期并发症。此外，成年ALL患者的生存率仍低于40%。因此，需要新的治疗策略来不仅提高治愈率，还改善这些患者的生活质量。在此，我们讨论可能改善ALL患者临床结局的新兴新疗法。这些包括现有化疗药物的新剂型、新的抗代谢物和核苷类似物、针对白血病相关抗原的单克隆抗体，以及针对白血病细胞及其受影响信号通路基因异常的分子疗法。
